Neurology · Pain ManagementRegulatory Approvalcommercialnear-term

FDA Approves Pregabalin ANDA219593 by Unichem

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/11/2026, 6:32:18 PM

Assessment confidence: 51% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

The FDA's approval of Unichem's generic Pregabalin introduces significant competition in the pain management market. This could lead to pricing pressures and market share erosion for existing branded products, necessitating strategic adjustments from portfolio teams. Regulatory context from FDA (FDA AP — PREGABALIN (ORIG)) supports the near-term read. Assessment grounded in 4 ranked evidence items (1 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this generic entry on pricing and market share for branded Pregabalin products. The strongest clinical anchor is The Effect of Training Given to Nurses Caring for Patients Receiving Palliative Care on Pain Management Self-Efficacy (ClinicalTrials.gov), sub-indication match (pain). In pain, 2 regulatory and 1 competitive items passed relevance filtering for Unichem.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). This approval allows Unichem to market a generic version of Pregabalin, increasing competition in the pain management market.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — PREGABALIN (ORIG) (FDA). Entity match (unichem); Regulatory pathway relevance (nda). While the approval itself is a standard regulatory process, the implications for market competition and compliance with pricing regulations will need ongoing attention.

Key Risks

Elevated medium regulatory exposure for Unichem could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The entry of a generic version of Pregabalin is likely to disrupt pricing structures and could significantly impact revenue for current branded products, affecting overall market dynamics.
Portfolio teams should assess the impact of this generic entry on pricing and market share for branded Pregabalin products.

What Would Change This Assessment

This becomes more urgent if Monitor market entry timing and pricing strategies from Unichem and competitors.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — PREGABALIN (ORIG)
FDAmedium relevance
Entity match (unichem); Regulatory pathway relevance (nda)
FDA document
View source
FDA Approves First Treatment for COVID-19
FDAmedium relevance
Regulatory pathway relevance (approval)
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA Approves New Treatment to Reduce Proteinuria in Adults with Primary Immunoglobulin A Nephropathy
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

The Effect of Training Given to Nurses Caring for Patients Receiving Palliative Care on Pain Management Self-Efficacy
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Effects of Pregabalin Ultrasound Therapy and Nerve Exercises on Pain and Sensation in Diabetic Nerve Damage
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Prevalence and Risk Factors for Chronic Post-Surgical Pain Following Video-Assisted Thoracic Surgery : The EVATHO Prospective Bicentric Cohort Study.
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of Different Myofascial Release Techniques on Function in Chronic Non-Specific Neck Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Vibratory Anesthesia on Pain Following Corticosteroid Injections
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Clinical Trial to Investigate the Efficacy and Safety of Plant-derived Cetylated Fatty Acids (CFA) on Knee Pain and Stiffness in Healthy Adults With Persistent Knee Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizermedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Approves Veklury as First Treatment for COVID-19
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities
FDA Approves Isatuximab-irfc Subcutaneous Injection for Multiple Myeloma
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Immunogenicity and safety of a 2 + 1 schedule of the DTaP-IPV-HB-Hib hexavalent combination vaccine in preterm infants in Spain.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Factors predicting health-enhancing physical activity in patients with chronic widespread pain following a person-centred health plan.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Unichem

Commercial impact

high

The entry of a generic version of Pregabalin is likely to disrupt pricing structures and could significantly impact revenue for current branded products, affecting overall market dynamics.

Regulatory impact

medium

While the approval itself is a standard regulatory process, the implications for market competition and compliance with pricing regulations will need ongoing attention.

What to watch

Monitor market entry timing and pricing strategies from Unichem and competitors.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.